Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial.

MLA

Allahyari, Abolghasem, et al. “Comparing Efficacy and Safety of P013, a Proposed Pertuzumab Biosimilar, with the Reference Product in HER2-Positive Breast Cancer Patients: A Randomized, Phase III, Equivalency Clinical Trial.” BMC Cancer, vol. 22, no. 1, Sept. 2022, p. 960. EBSCOhost, https://doi.org/10.1186/s12885-022-09895-5.

APA

Allahyari, A., Ehsanpour, A., Najafi, B., Ansarinejad, N., Mehrzad, V., Kalantari, B., Raafat, J., Ghadiany, M., Shahi, F., Gharib, B., Moazed, V., Khosravi, A., Mirpour, M. H., Salari, S., Mortazavizadeh, S., Nekoyi, A., Khani, M., Sadeghi, A., Gharib, S., … Najafi, S. (2022). Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial. BMC Cancer, 22(1), 960. https://doi.org/10.1186/s12885-022-09895-5

Chicago

Allahyari, Abolghasem, Ali Ehsanpour, Behrouz Najafi, Nafiseh Ansarinejad, Valiollah Mehrzad, Behjat Kalantari, Jahangir Raafat, et al. 2022. “Comparing Efficacy and Safety of P013, a Proposed Pertuzumab Biosimilar, with the Reference Product in HER2-Positive Breast Cancer Patients: A Randomized, Phase III, Equivalency Clinical Trial.” BMC Cancer 22 (1): 960. doi:10.1186/s12885-022-09895-5.